Why choose CF-EU2v1?
- CE-IVD ensures reliability
- Clinically relevant with 80-90% coverage of the most prevalent mutations (region dependent)
- Available population-specific bolt on panels
- Fast turnaround time
- Simple set up, minimal hands on time and ease of use
- Fits comfortably into existing patient care pathways, with low DNA input volume
- Users can expect consistency across results – ease of interpretation
- Data review using GeneMapper™ and GeneMarker® software (no data transfer required)
Performance you can rely on
100% Accuracy, Repeatability & Reproducibility
100% Accuracy, Repeatability & Reproducibility
| Positive Percent Agreement (PPA) | Negative Percent Agreement (NPA) | Overall Agreement (OA) | |
|---|---|---|---|
|
Accuracy |
100% |
100% |
100% |
|
Repeatability |
100% |
100% |
100% |
|
Reproducibility |
100% |
100% |
100% |
Accuracy was compared to Sanger sequencing. Accuracy of the CF-EU2v1 assay was assessed by evaluating 159 samples representing a wide variety of CFTR gene variants from 4 separate sources.